Russell Wiesner

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Evolving concepts in the diagnosis, pathogenesis, and treatment of chronic hepatic allograft rejection
    R H Wiesner
    Division of Liver Transplantation, Mayo Clinic, Rochester, MN 55905, USA
    Liver Transpl Surg 5:388-400. 1999
  2. ncbi request reprint Recent advances in liver transplantation
    Russell H Wiesner
    Division of Gastroenterology and Hepatology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:197-210. 2003
  3. ncbi request reprint Model for end-stage liver disease (MELD) and allocation of donor livers
    Russell Wiesner
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Gastroenterology 124:91-6. 2003
  4. ncbi request reprint Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy
    Russell H Wiesner
    William J von Liebig Transplant Center, Mayo Clinic, 200 First Street, SW, Rochester, Minnesota 55905, USA
    Gastroenterology 127:S261-7. 2004
  5. ncbi request reprint Mycophenolate mofetil use is associated with decreased risk of late acute rejection in adult liver transplant recipients
    R H Wiesner
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
    Am J Transplant 6:1609-16. 2006
  6. ncbi request reprint Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C
    Russell H Wiesner
    Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Liver Transpl 11:750-9. 2005
  7. ncbi request reprint Patient selection in an era of donor liver shortage: current US policy
    Russell H Wiesner
    Mayo Clinic Transplant Center, Rochester, MN 55905, USA
    Nat Clin Pract Gastroenterol Hepatol 2:24-30. 2005
  8. ncbi request reprint A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients
    R Wiesner
    Mayo Clinic, Rochester, MN 55905, USA
    Liver Transpl 7:442-50. 2001
  9. pmc Noninvasive diagnosis of acute cellular rejection in liver transplant recipients: a proteomic signature validated by enzyme-linked immunosorbent assay
    Omar Massoud
    Division of Gastroenterology and Hepatology, University of Alabama at Birmingham, Birmingham, AL, USA
    Liver Transpl 17:723-32. 2011
  10. ncbi request reprint Predicting survival among patients listed for liver transplantation: an assessment of serial MELD measurements
    Kiran Bambha
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN, USA
    Am J Transplant 4:1798-804. 2004

Collaborators

Detail Information

Publications51

  1. ncbi request reprint Evolving concepts in the diagnosis, pathogenesis, and treatment of chronic hepatic allograft rejection
    R H Wiesner
    Division of Liver Transplantation, Mayo Clinic, Rochester, MN 55905, USA
    Liver Transpl Surg 5:388-400. 1999
    ..Newer immunosuppressive agents, such as tacrolimus and mycophenolate, may successfully reverse chronic rejection, particularly when it is diagnosed in its early histological stages...
  2. ncbi request reprint Recent advances in liver transplantation
    Russell H Wiesner
    Division of Gastroenterology and Hepatology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:197-210. 2003
    ..However, these therapies have been fraught with metabolic complications that are now affecting quality of life and long-term survival. Tailoring immunosuppressive regimens to the individual patient is discussed...
  3. ncbi request reprint Model for end-stage liver disease (MELD) and allocation of donor livers
    Russell Wiesner
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Gastroenterology 124:91-6. 2003
    ..Our aim was to assess the capability of the Model for End-Stage Liver Disease (MELD) score to correctly rank potential liver recipients according to their severity of liver disease and mortality risk on the OPTN liver waiting list...
  4. ncbi request reprint Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy
    Russell H Wiesner
    William J von Liebig Transplant Center, Mayo Clinic, 200 First Street, SW, Rochester, Minnesota 55905, USA
    Gastroenterology 127:S261-7. 2004
    ..It is hoped that through continued data collection and assessment, a consensus can be reached to further optimize the use of deceased donors in HCC recipients...
  5. ncbi request reprint Mycophenolate mofetil use is associated with decreased risk of late acute rejection in adult liver transplant recipients
    R H Wiesner
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
    Am J Transplant 6:1609-16. 2006
    ..0% vs. 87.0%, p < 0.001) and no rejection (88.1%, p < 0.001). Three-drug versus 2-drug therapy for a minimum of 6 months may offer a better treatment strategy to avoid the consequences and expense of LAR episodes...
  6. ncbi request reprint Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C
    Russell H Wiesner
    Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Liver Transpl 11:750-9. 2005
    ..In conclusion, the addition of MMF at discharge to tacrolimus-based immunosuppression is associated with improved long-term outcomes after liver transplantation in patients with and without HCV...
  7. ncbi request reprint Patient selection in an era of donor liver shortage: current US policy
    Russell H Wiesner
    Mayo Clinic Transplant Center, Rochester, MN 55905, USA
    Nat Clin Pract Gastroenterol Hepatol 2:24-30. 2005
    ..So far, this new allocation system has been a success, but it does have its shortcomings, and even with improvements to the system, the use of the donor organ pool still needs to be optimized...
  8. ncbi request reprint A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients
    R Wiesner
    Mayo Clinic, Rochester, MN 55905, USA
    Liver Transpl 7:442-50. 2001
    ..MMF and AZA were equivalent in preventing graft loss at 1 year, and the safety profiles between the two immunosuppressive agents were similar...
  9. pmc Noninvasive diagnosis of acute cellular rejection in liver transplant recipients: a proteomic signature validated by enzyme-linked immunosorbent assay
    Omar Massoud
    Division of Gastroenterology and Hepatology, University of Alabama at Birmingham, Birmingham, AL, USA
    Liver Transpl 17:723-32. 2011
    ..In summary, in this exploratory analysis, serum C4 and ALT levels were highly predictive of ACR in liver transplant recipients. Confirmation in a prospective, larger, and diverse population is needed...
  10. ncbi request reprint Predicting survival among patients listed for liver transplantation: an assessment of serial MELD measurements
    Kiran Bambha
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN, USA
    Am J Transplant 4:1798-804. 2004
    ..Delta MELD is predictive of death only within 4 d of the event; however, part of this correlates with the dying process itself, thus limiting Delta MELD's utility in survival prediction models...
  11. ncbi request reprint Natural history and management of hepatitis C infection after liver transplantation
    Michael Charlton
    Department of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Semin Liver Dis 24:79-88. 2004
    ..This article describes the natural history, risk factors, and current strategies for the amelioration of posttransplant HCV infection...
  12. ncbi request reprint The pathogenesis of hepatitis C virus is influenced by cytomegalovirus
    Raymund R Razonable
    Division of Infectious Diseases and Internal Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Clin Infect Dis 35:974-81. 2002
    ..05) and had a trend toward a higher hepatitis activity index (P=.10) and HCV load (P=.10) at 16 weeks after liver transplantation. The pathogenesis of HCV is influenced by its interaction with CMV but not with HHV-6...
  13. ncbi request reprint Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C
    Kelly W Burak
    Transplant Center, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Liver Transpl 8:362-9. 2002
    ..Whether CMV mediates this by inducing increased immunosuppression or directly enhancing HCV replication requires further study...
  14. ncbi request reprint MELD accurately predicts mortality in patients with alcoholic hepatitis
    Winston Dunn
    Advanced Liver Disease Study Group, Mayo Clinic, Rochester, MN 55905, USA
    Hepatology 41:353-8. 2005
    ..MELD is a useful clinical tool for gauging mortality and guiding treatment decisions in patients with AH, particularly those complicated by ascites and/or encephalopathy...
  15. ncbi request reprint Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy
    Kozhikode V Narayanan Menon
    Liver Transplant Center, Mayo Clinic and Foundation, Rochester, MN 55902, USA
    Liver Transpl 8:623-9. 2002
    ..The majority of patients require dose modifications because of side effects. Histological response is common in virological nonresponders...
  16. ncbi request reprint Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database
    Michael Charlton
    Liver Transpl 10:1120-30. 2004
    ..Long-term death and graft loss specifically secondary to recurrence of HCV appears, however, to be determined primarily by factors other than those included in this analysis...
  17. ncbi request reprint Summary report of a national conference: Evolving concepts in liver allocation in the MELD and PELD era. December 8, 2003, Washington, DC, USA
    Kim M Olthoff
    Department of Surgery, Division of Transplantation, University of Pennsylvania, Philadelphia, PA, USA
    Liver Transpl 10:A6-22. 2004
    ..Recommendations for the transplant community, based on the analysis of the MELD data, were discussed and are presented in the summary document...
  18. ncbi request reprint MELD/PELD and the allocation of deceased donor livers for status 1 recipients with acute fulminant hepatic failure, primary nonfunction, hepatic artery thrombosis, and acute Wilson's disease
    Russell H Wiesner
    Department of Medicine, Mayo Clinic, Von Liebig Transplant Center, Rochester, MN, USA
    Liver Transpl 10:S17-22. 2004
    ..4. Outcomes of adults listed as Status 1 in the United States. 5. Outcomes of pediatric candidates listed as Status 1 in the United States. 6. Proposed redefinition for Status 1 in adult and pediatric candidates...
  19. ncbi request reprint Preliminary results: outcome of liver transplantation for hepatitis B virus varies by hepatitis B virus genotype
    Harshad C Devarbhavi
    Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Liver Transpl 8:550-5. 2002
    ..Patients with genotype D appear to have the highest risk for HBV recurrence and mortality. Additional larger multicenter studies are needed to confirm these findings...
  20. ncbi request reprint Liver allograft iron accumulation in patients with and without pretransplantation hepatic hemosiderosis
    Monica B Parolin
    Division of Gastroenterology, Hepatology, and Liver Transplantation, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Liver Transpl 8:331-9. 2002
    ..There was a suggestion that patients with severe pre-OLT hemosiderosis had a greater frequency of iron accumulation in late hepatic biopsy specimens...
  21. ncbi request reprint Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial
    Carlos V Paya
    Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Infect Dis 185:854-60. 2002
    ..02), compared with 11% and 0% of such patients in the ganciclovir arm (P <.01). Oral ganciclovir administered on CMV detection by PCR prevents CMV infection or disease after liver transplantation...
  22. ncbi request reprint Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis
    John R Lake
    Gastroenterology Division, University of Minnesota, Minneapolis, Minnesota, USA
    Am J Transplant 5:549-57. 2005
    ..There are clear differences in risk factors for poor outcomes based on underlying liver disease, particularly with regard to the impact of donor age...
  23. ncbi request reprint Evidence-based evolution of the MELD/PELD liver allocation policy
    Russell H Wiesner
    Liver Transpl 11:261-3. 2005
  24. ncbi request reprint Results of the first year of the new liver allocation plan
    Richard B Freeman
    Tufts University School of Medicine, New England Medical Center, Division of Transplantation, Boston, MA 02111, USA
    Liver Transpl 10:7-15. 2004
    ....
  25. ncbi request reprint Portopulmonary hypertension: Results from a 10-year screening algorithm
    Michael J Krowka
    Divisions of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hepatology 44:1502-10. 2006
    ..g., high flow and increased central volume) in liver transplantation candidates. Severity of POPH correlates poorly with MELD scores...
  26. ncbi request reprint Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation
    Phunchai Charatcharoenwitthaya
    Miles and Shirley Fitterman Center for Digestive Diseases, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Liver Transpl 13:1236-45. 2007
    ..In this short period of treatment, UDCA was not associated with improved patient and graft survival compared to untreated patients...
  27. pmc Celiac disease autoantibodies in severe autoimmune liver disease and the effect of liver transplantation
    Alberto Rubio-Tapia
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Liver Int 28:467-76. 2008
    ....
  28. doi request reprint Long-term outcome of human leukocyte antigen mismatching in liver transplantation: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database
    Vijayan Balan
    Department of Transplantation Medicine, Mayo Clinic, Phoenix, AZ, USA
    Hepatology 48:878-88. 2008
    ..01, HR = 4.2) and primary biliary cirrhosis (P = 0.04, HR = 2). Mismatch in the A locus was associated with more recurrence of hepatitis C virus (P = 0.01, HR = 1.6) and primary sclerosing cholangitis (P = 0.03, HR = 2.9)...
  29. doi request reprint Hyponatremia and mortality among patients on the liver-transplant waiting list
    W Ray Kim
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    N Engl J Med 359:1018-26. 2008
    ..Under the current liver-transplantation policy, donor organs are offered to patients with the highest risk of death...
  30. ncbi request reprint MELD and other factors associated with survival after liver transplantation
    K V Narayanan Menon
    The William J von Liebig Transplant Center, Mayo Clinic and Foundation, Rochester, Minnesota, USA
    Am J Transplant 4:819-25. 2004
    ..In multivariate models, age, underlying etiology of liver disease and renal failure requiring hemodialysis were independent predictors of death after OLT...
  31. ncbi request reprint A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis
    K V Narayanan Menon
    Advanced Liver Disease Study Group, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 99:255-60. 2004
    ....
  32. ncbi request reprint The new liver allocation system: moving toward evidence-based transplantation policy
    Richard B Freeman
    Department of Surgery, Tufts New England Medical Center Tufts University School of Medicine, Boston, MA, USA
    Liver Transpl 8:851-8. 2002
    ..Application of such risk models provides an evidenced-based approach on which to base further refinements and improve the model...
  33. ncbi request reprint Differential allograft gene expression in acute cellular rejection and recurrence of hepatitis C after liver transplantation
    Raghavakaimal Sreekumar
    Transplant Center, Mayo Clinic and Foundation, Rochester, MN, USA
    Liver Transpl 8:814-21. 2002
    ..Further studies are required to determine whether gene expression profiles, either intragraft or in serum, can be used for the diagnosis and differentiation of ACR from recurrence of HCV...
  34. ncbi request reprint Effect of minimal listing criteria on waiting list registration for liver transplantation: a process-outcome analysis
    Jayant A Talwalkar
    Transplant Center, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:431-5. 2003
    ..To determine the level of association between minimal listing criteria (MLC) recognition and outcomes associated with waiting list registration for liver transplantation (LT)...
  35. ncbi request reprint Liver and intestine transplantation
    John P Roberts
    University of California San Francisco, San Francisco, CA, USA
    Am J Transplant 3:78-90. 2003
  36. ncbi request reprint Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir
    Raymund R Razonable
    Division of Infectious Diseases and Internal Medicine, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    J Infect Dis 187:1801-8. 2003
    ..This study identifies a relative cutoff virus load that predicts subsequent development of CMV disease and highlights the inability of oral ganciclovir to suppress CMV replication in a subset of patients...
  37. ncbi request reprint Improving liver allocation: MELD and PELD
    Richard B Freeman
    Tufts New England Medical Center, Boston, MA, USA
    Am J Transplant 4:114-31. 2004
    ..Children younger than 2 years, however, still have a considerably higher rate of death on the waiting list than adults. A limited definition of ECD livers suggests that they are used more frequently for patients with lower MELD scores...
  38. ncbi request reprint Acquired (non-Wilsonian) hepatocerebral degeneration: complex management decisions
    Eelco F M Wijdicks
    Department of Neurology and Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Liver Transpl 9:993-4. 2003
    ..In our liver transplantation program, we were recently confronted with such a case, and present herein not only the characteristic magnetic resonance imaging findings but also some of the dilemmas of management...
  39. ncbi request reprint Recurrence of primary biliary cirrhosis after liver transplantation: Histologic estimate of incidence and natural history
    Pamela B Sylvestre
    Division of Anatomic Pathology, Mayo Clinic and Foundation, Rochester, MN, USA
    Liver Transpl 9:1086-93. 2003
    ..7 years of follow-up. When criteria for histologic recurrence are expanded to include moderate lymphocytic cholangitis with lymphoplasmacytic portal infiltrate, the recurrence rate of PBC is estimated as 26%...
  40. ncbi request reprint Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C
    Russell H Wiesner
    Liver Transpl 9:S1-9. 2003
  41. ncbi request reprint Subclinical reactivation of hepatitis B virus in liver transplant recipients with past exposure
    Manal F Abdelmalek
    Division of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, AZ, USA
    Liver Transpl 9:1253-7. 2003
    ..In our experience, infected donor livers are the most common source of de novo posttransplantation hepatitis B infection in transplant recipients...
  42. ncbi request reprint MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients
    Walter K Kremers
    The William J von Liebig Transplant Center, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA
    Hepatology 39:764-9. 2004
    ..68). In conclusion, liver allocation within the Status 1 designation may need to be further stratified by diagnosis, and MELD score may be useful for prioritizing FHF-NA candidates...
  43. ncbi request reprint Liver transplantation for hepatocellular carcinoma: the MELD impact
    Pratima Sharma
    Division of Transplantation Medicine, Mayo Clinic, Scottsdale, AZ, USA
    Liver Transpl 10:36-41. 2004
    ..Furthermore, the 5-month dropout rate has decreased significantly. In addition, 5-month survival while waiting has increased in the post-MELD period. Thus, the new MELD-based allocation policy has benefited HCC candidates...
  44. ncbi request reprint Chronic renal dysfunction late after liver transplantation
    Ari J Cohen
    Department of Surgery, Division of Transplantation, Mayo Clinic, Rochester, MN 55905, USA
    Liver Transpl 8:916-21. 2002
    ..Patients with a low GFR at 1 year (< 40 mL/min/BSA) are a high-risk group that might benefit from early therapeutic interventions aimed at preventing subsequent renal failure...
  45. ncbi request reprint Analysis of factors that predict alcohol relapse following liver transplantation
    Sameer Jauhar
    University of Glasgow, Scotland, UK
    Liver Transpl 10:408-11. 2004
    ..03). Further prospective studies are needed to examine this association in greater detail to provide targeted treatment for alcoholism both before and after liver transplantation...
  46. ncbi request reprint Prevention of post-transplant cardiovascular disease--report and recommendations of an ad hoc group
    Andrew D Bostom
    Department of Surgery, University of Minnesota, MMC 328 Mayo, Minneapolis 55455, USA
    Am J Transplant 2:491-500. 2002
  47. ncbi request reprint Outcome of liver transplantation for familial amyloidotic polyneuropathy
    Pratima Sharma
    Division of Transplant Medicine, Mayo Clinic, Scottsdale, AZ, USA
    Liver Transpl 9:1273-80. 2003
    ..Outcomes for LT for patients with FAP with MET or NMET mutations were similar. Earlier LT for patients with FAP with MET30 or NMET30 mutation would improve outcomes after LT...
  48. ncbi request reprint Curricular guidelines for training in transplant hepatology
    Hugo R Rosen
    Liver and Intra Abdominal Subcommittee, American Society for Transplantation, USA
    Liver Transpl 8:85-7. 2002
  49. ncbi request reprint Pirfenidone in the treatment of primary sclerosing cholangitis
    Paul Angulo
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota P 55905, USA
    Dig Dis Sci 47:157-61. 2002
    ..Pirfenidone did not benefit patients with PSC, and it was frequently associated with adverse events. The results of this pilot study discourage further trials of pirfenidone in patients with PSC...
  50. ncbi request reprint Natural history of hepatopulmonary syndrome: Impact of liver transplantation
    Karen L Swanson
    Division of Pulmonary and Critical Care, Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hepatology 41:1122-9. 2005
    ..In conclusion, hypoxemia of HPS is frequently progressive. As OLT outcome relates to pretransplantation PaO(2), additional MELD points should advance the priority for OLT in HPS...
  51. ncbi request reprint Risk factors for and clinical course of non-anastomotic biliary strictures after liver transplantation
    Maureen M J Guichelaar
    Division of Liver Transplantation, Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Am J Transplant 3:885-90. 2003
    ..A pretransplant diagnosis of autoimmune hepatitis has been identified as a novel independent risk factor for NAS formation. Development of NAS significantly attenuates graft but not patient survival...